New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis

Franco Frati, Lorenzo Cecchi, Enrico Scala, Erminia Ridolo, Ilaria Dell’Albani, Eleni Makrì, Giovanni Pajno, Cristoforo Incorvaia

Research output: Contribution to journalArticle

Abstract

The molecular allergy technique, currently defined as component-resolved diagnosis, significantly improved the diagnosis of allergy, allowing for differentiation between molecules actually responsible for clinical symptoms (genuine sensitizers) and those simply cross-reacting or shared by several sources (panallergens), thus influencing the appropriate management of a patient’s allergy. This also concerns allergen immunotherapy (AIT), which may be prescribed more precisely based on the component-resolved diagnosis results. However, the advance in diagnosis needs to be mirrored in AIT. According to consensus documents and to expectations of specialists, therapy should be based on standardized extracts containing measured amounts of the clinically relevant molecules, ie, the major allergens. The new generation of extracts for sublingual immunotherapy fulfills these requirements and are thus defined as biomolecular (BM). BM refers to natural extracts with a defined content of major allergens in micrograms. All Staloral BM products are indicated for the treatment of allergic rhinitis with or without asthma. The effectiveness of AIT is related to its ability to modify the immunological response of allergic subjects. The 5-grass and house dust mite extracts were evaluated addressing the T helper 1, T helper 2, and T helper 3 cells by polymerase chain reaction array on mRNA extracted from Waldeyer’s ring tissue (adenoids). Sublingual immunotherapy with a defined content of major allergens in micrograms induced a strong downregulation of genes involved in T helper 2 and T helper 1 activation and function, allowing the definition of the immunologic effect as “bio-homeostatic”. This clinical and immunological model must be implemented with respect to other allergens, thus expanding the application of a treatment with a unique disease-modifying capacity.

Original languageEnglish
Pages (from-to)221-226
Number of pages6
JournalBiologics: Targets and Therapy
Volume8
DOIs
Publication statusPublished - Sep 12 2014

Fingerprint

Sublingual Immunotherapy
Immunologic Desensitization
Allergens
Hypersensitivity
Immunological Models
Adenoids
Pyroglyphidae
Th2 Cells
Poaceae
Therapeutics
Down-Regulation
Asthma
Polymerase Chain Reaction
Messenger RNA
Allergic Rhinitis
Genes

Keywords

  • Allergen immunotherapy
  • Allergen molecules
  • Allergy
  • Component resolved diagnosis
  • Major allergens

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Pharmacology (medical)
  • Gastroenterology
  • Rheumatology

Cite this

New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis. / Frati, Franco; Cecchi, Lorenzo; Scala, Enrico; Ridolo, Erminia; Dell’Albani, Ilaria; Makrì, Eleni; Pajno, Giovanni; Incorvaia, Cristoforo.

In: Biologics: Targets and Therapy, Vol. 8, 12.09.2014, p. 221-226.

Research output: Contribution to journalArticle

Frati, Franco ; Cecchi, Lorenzo ; Scala, Enrico ; Ridolo, Erminia ; Dell’Albani, Ilaria ; Makrì, Eleni ; Pajno, Giovanni ; Incorvaia, Cristoforo. / New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis. In: Biologics: Targets and Therapy. 2014 ; Vol. 8. pp. 221-226.
@article{e88b50da747b40c2b01d5b8d815de96e,
title = "New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis",
abstract = "The molecular allergy technique, currently defined as component-resolved diagnosis, significantly improved the diagnosis of allergy, allowing for differentiation between molecules actually responsible for clinical symptoms (genuine sensitizers) and those simply cross-reacting or shared by several sources (panallergens), thus influencing the appropriate management of a patient’s allergy. This also concerns allergen immunotherapy (AIT), which may be prescribed more precisely based on the component-resolved diagnosis results. However, the advance in diagnosis needs to be mirrored in AIT. According to consensus documents and to expectations of specialists, therapy should be based on standardized extracts containing measured amounts of the clinically relevant molecules, ie, the major allergens. The new generation of extracts for sublingual immunotherapy fulfills these requirements and are thus defined as biomolecular (BM). BM refers to natural extracts with a defined content of major allergens in micrograms. All Staloral BM products are indicated for the treatment of allergic rhinitis with or without asthma. The effectiveness of AIT is related to its ability to modify the immunological response of allergic subjects. The 5-grass and house dust mite extracts were evaluated addressing the T helper 1, T helper 2, and T helper 3 cells by polymerase chain reaction array on mRNA extracted from Waldeyer’s ring tissue (adenoids). Sublingual immunotherapy with a defined content of major allergens in micrograms induced a strong downregulation of genes involved in T helper 2 and T helper 1 activation and function, allowing the definition of the immunologic effect as “bio-homeostatic”. This clinical and immunological model must be implemented with respect to other allergens, thus expanding the application of a treatment with a unique disease-modifying capacity.",
keywords = "Allergen immunotherapy, Allergen molecules, Allergy, Component resolved diagnosis, Major allergens",
author = "Franco Frati and Lorenzo Cecchi and Enrico Scala and Erminia Ridolo and Ilaria Dell’Albani and Eleni Makr{\`i} and Giovanni Pajno and Cristoforo Incorvaia",
year = "2014",
month = "9",
day = "12",
doi = "10.2147/BTT.S50951",
language = "English",
volume = "8",
pages = "221--226",
journal = "Biologics: Targets and Therapy",
issn = "1177-5475",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis

AU - Frati, Franco

AU - Cecchi, Lorenzo

AU - Scala, Enrico

AU - Ridolo, Erminia

AU - Dell’Albani, Ilaria

AU - Makrì, Eleni

AU - Pajno, Giovanni

AU - Incorvaia, Cristoforo

PY - 2014/9/12

Y1 - 2014/9/12

N2 - The molecular allergy technique, currently defined as component-resolved diagnosis, significantly improved the diagnosis of allergy, allowing for differentiation between molecules actually responsible for clinical symptoms (genuine sensitizers) and those simply cross-reacting or shared by several sources (panallergens), thus influencing the appropriate management of a patient’s allergy. This also concerns allergen immunotherapy (AIT), which may be prescribed more precisely based on the component-resolved diagnosis results. However, the advance in diagnosis needs to be mirrored in AIT. According to consensus documents and to expectations of specialists, therapy should be based on standardized extracts containing measured amounts of the clinically relevant molecules, ie, the major allergens. The new generation of extracts for sublingual immunotherapy fulfills these requirements and are thus defined as biomolecular (BM). BM refers to natural extracts with a defined content of major allergens in micrograms. All Staloral BM products are indicated for the treatment of allergic rhinitis with or without asthma. The effectiveness of AIT is related to its ability to modify the immunological response of allergic subjects. The 5-grass and house dust mite extracts were evaluated addressing the T helper 1, T helper 2, and T helper 3 cells by polymerase chain reaction array on mRNA extracted from Waldeyer’s ring tissue (adenoids). Sublingual immunotherapy with a defined content of major allergens in micrograms induced a strong downregulation of genes involved in T helper 2 and T helper 1 activation and function, allowing the definition of the immunologic effect as “bio-homeostatic”. This clinical and immunological model must be implemented with respect to other allergens, thus expanding the application of a treatment with a unique disease-modifying capacity.

AB - The molecular allergy technique, currently defined as component-resolved diagnosis, significantly improved the diagnosis of allergy, allowing for differentiation between molecules actually responsible for clinical symptoms (genuine sensitizers) and those simply cross-reacting or shared by several sources (panallergens), thus influencing the appropriate management of a patient’s allergy. This also concerns allergen immunotherapy (AIT), which may be prescribed more precisely based on the component-resolved diagnosis results. However, the advance in diagnosis needs to be mirrored in AIT. According to consensus documents and to expectations of specialists, therapy should be based on standardized extracts containing measured amounts of the clinically relevant molecules, ie, the major allergens. The new generation of extracts for sublingual immunotherapy fulfills these requirements and are thus defined as biomolecular (BM). BM refers to natural extracts with a defined content of major allergens in micrograms. All Staloral BM products are indicated for the treatment of allergic rhinitis with or without asthma. The effectiveness of AIT is related to its ability to modify the immunological response of allergic subjects. The 5-grass and house dust mite extracts were evaluated addressing the T helper 1, T helper 2, and T helper 3 cells by polymerase chain reaction array on mRNA extracted from Waldeyer’s ring tissue (adenoids). Sublingual immunotherapy with a defined content of major allergens in micrograms induced a strong downregulation of genes involved in T helper 2 and T helper 1 activation and function, allowing the definition of the immunologic effect as “bio-homeostatic”. This clinical and immunological model must be implemented with respect to other allergens, thus expanding the application of a treatment with a unique disease-modifying capacity.

KW - Allergen immunotherapy

KW - Allergen molecules

KW - Allergy

KW - Component resolved diagnosis

KW - Major allergens

UR - http://www.scopus.com/inward/record.url?scp=84907617777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907617777&partnerID=8YFLogxK

U2 - 10.2147/BTT.S50951

DO - 10.2147/BTT.S50951

M3 - Article

VL - 8

SP - 221

EP - 226

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

SN - 1177-5475

ER -